sar425899 sanofi dual glp-1 glucagon agonist Glucagon‐Like Peptide‐1 (GLP‐1)‐Based Therapeutics: Current Status and Future Opportunities beyond Type 2 Diabetes - Cheang - 2018 - ChemMedChem sar425899 sanofi glp-1 glucagon dual
Description
Patient preference data showing a strong bias towards oral therapies over injections 7,8 points to a broader redefinition of engagement, adherence and long-term management
The mentioned DPP-4 inhibitors are orally active, rapidly absorbed, and suitable for once daily or twice daily administration, leading to a DPP-4 inhibition of 7090% over 24 h
$239 ongoing Compounded tirzepatide injections $299 first month
Retatrutide is currently undergoing phase 3 clinical trials, which will involve larger, more diverse populations and longer follow-up periods
If something here raises a question, follow the links that feel most relevant and ignore the rest for now
Consider Zepbound, the more effective GLP-1 for weight loss
